Financial Ratios

STRIDES PHARMA SCIENCE LTD.

NSE : STARBSE : 532531ISIN CODE : INE939A01011Industry : Pharmaceuticals & DrugsHouse : Private
BSE889.457.3 (+0.83 %)
PREV CLOSE ( ) 882.15
OPEN PRICE ( ) 879.50
BID PRICE (QTY) 887.80 (8)
OFFER PRICE (QTY) 889.45 (48)
VOLUME 12841
TODAY'S LOW / HIGH ( )870.75 901.35
52 WK LOW / HIGH ( )330.35 903.8
NSE889.007.3 (+0.83 %)
PREV CLOSE( ) 881.70
OPEN PRICE ( ) 883.70
BID PRICE (QTY) 888.20 (16)
OFFER PRICE (QTY) 888.95 (4)
VOLUME 102752
TODAY'S LOW / HIGH( ) 873.45 901.00
52 WK LOW / HIGH ( )330 902.4
Select year
ParticularsMar2023Mar2022Mar2021Mar2020Mar2019
Operational & Financial Ratios
   Earnings Per Share (Rs)0.5220.078.7213.4312.78
   CEPS(Rs)10.8931.6919.8023.9522.05
   DPS(Rs)1.500.002.5014.003.00
   Book NAV/Share(Rs)380.46379.13361.65352.04362.84
   Tax Rate(%)107.23-737.7729.9111.85-1.22
Margin Ratios
   Core EBITDA Margin(%)4.463.878.5712.089.04
   EBIT Margin(%)3.994.849.5312.0210.87
   Pre Tax Margin(%)-3.491.096.018.067.35
   PAT Margin (%)0.259.104.217.117.44
   Cash Profit Margin (%)5.3014.389.5612.6812.84
Performance Ratios
   ROA(%)0.093.431.612.632.60
   ROE(%)0.145.422.453.763.57
   ROCE(%)1.562.184.355.034.27
   Asset Turnover(x)0.340.380.380.370.35
   Sales/Fixed Asset(x)1.601.851.922.032.16
   Working Capital/Sales(x)5.6314.7812.12-27.775.60
Efficiency Ratios
   Fixed Capital/Sales(x)0.620.540.520.490.46
   Receivable days256.27195.32145.14133.56122.49
   Inventory Days98.79110.86113.17100.9888.19
   Payable days220.46228.47226.09204.46186.92
Valuation Parameters
   PER(x)551.8817.2796.8024.0236.92
   PCE(x)26.2910.9442.6513.4721.39
   Price/Book(x)0.750.912.340.921.30
   Yield(%)0.520.000.304.340.64
   EV/Net Sales(x)2.072.194.512.153.16
   EV/Core EBITDA(x)21.0821.7030.3312.2119.13
   EV/EBIT(x)52.0545.3547.3517.8629.03
   EV/CE(x)0.700.811.630.791.06
   M Cap / Sales1.391.574.081.712.75
Growth Ratio
   Net Sales Growth(%)-6.296.549.7910.054.62
   Core EBITDA Growth(%)-8.78-27.58-7.1317.30-28.20
   EBIT Growth(%)-22.80-45.90-12.9421.64-32.09
   PAT Growth(%)-97.40130.30-34.955.13-26.87
   EPS Growth(%)-97.42130.02-35.035.11-26.91
Financial Stability Ratios
   Total Debt/Equity(x)0.390.370.270.270.25
   Current Ratio(x)1.181.071.100.961.20
   Quick Ratio(x)0.910.790.660.640.86
   Interest Cover(x)0.531.292.713.043.09
   Total Debt/Mcap(x)0.520.400.120.300.19

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.